In October 2018, Coherent Biopharma completed its Series A2 fundraising of 20 million USD led by 6 Dimensions Capital to facilitate the clinical study projects and expand the pre-clinical product pipelines.
In October 2018, Coherent Biopharma completed its Series A2 fundraising of 20 million USD led by 6 Dimensions Capital, increasing the total fund raised in Series A to 28 million USD. Fund raised in the current series shall be used in broadening the current clinical pipelines (including clinical trials launch and overseas application), building the pre-clinical product and new drug R&D center and expanding the technology platform.
Founded in 2016, Coherent Biopharma is a pharmaceutical company dedicated to the development of new generation targeted medicine for tumors. On its BESTTM (Bi-Engaging ligand-mediated Selective Targeting) technology platform with independent IPR ownership, the Company’s the first Class I innovative drug CBP-1008 has entered into clinical study phase while multiple investigational drugs targeting at breast cancer, ovarian cancer, lung cancer as well as prostate and gastrointestinal tumors are in the pre-clinical phase.
Chair and General Manager Dr. Huang Baohua expressed thanks for the recognition of 6 Dimensions Capital and for the consistent interest and support from all shareholders. Funds raised in this series would significantly accelerate the R&D of products in clinical study phase and expand the pre-clinical product pipeline. It is believed that construction of the advanced R&D center for new drugs and engagement of high-level innovative talents will further expand the technology platform of Coherent Biopharma, ushering it into the fast track of new drug R&D with more breakthroughs.